SHANGHAI, July 19, 2024 /PRNewswire/ -- Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced the completion of $35 Million Series A+ financing. This round was led by LongRiver Investments, with participation from investors including Zhaode Investment, BioTrack Capital, Zhongqi Capital and Lilly Asia Ventures.
After raising $33 million back in April, Shanghai-based Rona Therapeutics is using some of that money to acquire a small interfering RNA (siRNA) platform and four preclinical candidates from Sanofi.